Conexeu Sciences (CNXU) vs Polaryx Therapeutics (PLYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Conexeu Sciences is the larger company by market cap ($109.7 million vs $99.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNXU | PLYX |
|---|---|---|
| Share price | $3.89 | $2.00 |
| Market cap | $109.72M | $99.69M |
| 1-day change | +12.75% | 0.00% |
| EPS (TTM) | $-0.61 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.79 | $48.91 |
| 52-week low | $3.05 | $1.85 |
| Distance from 52-week high | -79.30% | -95.91% |
| Analyst consensus | none | none |
| Avg. price target upside | +414.14% | +275.00% |
| Average volume | 211.83K | 74.54K |
| Shares outstanding | 28.21M | 49.85M |
| Employees | — | 2 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Conexeu Sciences
CNXU stock →Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair.
Health Care · Industrial Specialties
About Polaryx Therapeutics
PLYX stock →Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
CNXU vs PLYX FAQ
Which is bigger, Conexeu Sciences or Polaryx Therapeutics?
Conexeu Sciences (CNXU) is larger, with a market capitalization of $109.72M compared with $99.69M for Polaryx Therapeutics (PLYX).
Are Conexeu Sciences and Polaryx Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Industrial Specialties for Conexeu Sciences and Biotechnology: Pharmaceutical Preparations for Polaryx Therapeutics.